KOKI-Richter joint success: results of a team led by Professor Vizi in the British Journal of Pharmacology diakép
The XXVI KOKI Days in Várgesztes diakép
IEM - Weizmann Brain Sciences Workshop 2024 diakép
Our microscopists and the European Microscopy Conference in Copenhagen (EMC2024) diakép
History of the "Human Hair Bulb Project" diakép

KOKI-Richter joint success: results of a team led by Professor Vizi in the British Journal of Pharmacology

Tetrabenazine, a VMAT-2 enzyme inhibitor, is used to treat sudden movements caused by neurodegenerative diseases called Huntington's disease and tardive dyskinesia, which are uncontrollable by the individual. The extent to which this drug inhibits the release of the monoamines noradrenaline, dopamine, and serotonin in different brain areas is not yet known. This is what a collaboration between the Sperlágh group and researchers at Richter Gedeon Nyrt led by Szilveszter E. Vizi investigated. The significance of the result is underlined by the fact that the work, first submitted by Pál Tod and with corresponding authorship by Professor Vizi, was published in the leading international journal of pharmacology.

 

 

Details

Research groups

In the 20 research groups of the institute 102 researcher, 39 PhD student and several student research assistants work

News, articles

Research areas

Research projects in the Institute are ordered into 5 strategical directions: stress, memory, endocrine systems, the relationship between the nervous and immune system, the neuroscience of social behavior
70
Publications (2023)
8 276
Citations (2023)
102
Scientists
39
PhD students

Our partners